{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T20:29:11Z","timestamp":1786566551613,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025230","name":"Biotest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtcvs.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:13:36Z","timestamp":1784204016000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes and treatment of early detectable donor-specific antihuman leukocyte antigen antibodies after lung transplantation: Insights from a 12-year experience"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3607-977X","authenticated-orcid":false,"given":"Catharina","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0297-6204","authenticated-orcid":false,"given":"Sophie","family":"Kruszona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-8146","authenticated-orcid":false,"given":"Nunzio D.","family":"de Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-2045","authenticated-orcid":false,"given":"Murielle","family":"Verboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Walloschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7555-218X","authenticated-orcid":false,"given":"Michael","family":"Hallensleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Carlens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-8348","authenticated-orcid":false,"given":"Dmitry","family":"Bobylev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-7749","authenticated-orcid":false,"given":"Nicolaus","family":"Schwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-7318","authenticated-orcid":false,"given":"Christine","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-9912","authenticated-orcid":false,"given":"Arjang","family":"Ruhparwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Avsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3234-306X","authenticated-orcid":false,"given":"Mark","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Aburahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtcvs.2026.07.002_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.healun.2014.06.015","article-title":"Early donor-specific antibodies in lung transplantation: risk factors and impact on survival","volume":"33","author":"Ius","year":"2014","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.jtcvs.2026.07.002_bib2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.healun.2016.05.020","article-title":"De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome","volume":"35","author":"Le Pavec","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jtcvs.2026.07.002_bib3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/ajt.13589","article-title":"Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics","volume":"16","author":"Roux","year":"2016","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.jtcvs.2026.07.002_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01248-2017","article-title":"Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation","volume":"50","author":"Verleden","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jtcvs.2026.07.002_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01898-2017","article-title":"Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome","volume":"52","author":"Brugi\u00e8re","year":"2018","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.jtcvs.2026.07.002_bib6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.healun.2020.09.003","article-title":"Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction","volume":"39","author":"Iasella","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jtcvs.2026.07.002_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.12973","article-title":"Antibody-mediated rejection in lung transplantation: diagnosis and therapeutic armamentarium in a 21st century perspective","volume":"37","author":"Messika","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.jtcvs.2026.07.002_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.12774","article-title":"Impact of transient and persistent donor-specific antibodies in lung transplantation","volume":"37","author":"Auner","year":"2024","journal-title":"Transpl Int"},{"issue":"10","key":"10.1016\/j.jtcvs.2026.07.002_bib9","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1111\/ajt.16707","article-title":"Long-term outcomes of sensitized lung transplant recipients after peri-operative desensitization","volume":"21","author":"Aversa","year":"2021","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.jtcvs.2026.07.002_bib10","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ajt.2023.04.034","article-title":"Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experience","volume":"23","author":"Heise","year":"2023","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.jtcvs.2026.07.002_bib11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.healun.2013.07.004","article-title":"Acute antibody-mediated rejection after lung transplantation","volume":"32","author":"Witt","year":"2013","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.jtcvs.2026.07.002_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12886","article-title":"Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: does it work?","volume":"31","author":"Vacha","year":"2017","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.jtcvs.2026.07.002_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001131","article-title":"Assessment of carfilzomib treatment response in lung transplant recipients with antibody-mediated rejection","volume":"7","author":"Pham","year":"2021","journal-title":"Transplant Direct"},{"issue":"6","key":"10.1016\/j.jtcvs.2026.07.002_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22151","article-title":"Efficacy of a standardized regimen of therapeutic plasma exchange and IVIG for treatment of antibody-mediated rejection in lung transplant recipients","volume":"39","author":"Wodajo","year":"2024","journal-title":"J Clin Apher"},{"issue":"10","key":"10.1016\/j.jtcvs.2026.07.002_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.healun.2023.05.012","article-title":"Tocilizumab for antibody-mediated rejection treatment in lung transplantation","volume":"42","author":"January","year":"2023","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.jtcvs.2026.07.002_bib16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/TP.0000000000000392","article-title":"Antibody-mediated rejection in lung transplantation: fable, spin, or fact?","volume":"98","author":"Westall","year":"2014","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.jtcvs.2026.07.002_bib17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.healun.2010.05.006","article-title":"Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation","volume":"29","author":"Hachem","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jtcvs.2026.07.002_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.13431","article-title":"Preemptive treatment of de novo donor specific anti-HLA antibodies with IVIG monotherapy after lung transplantation","volume":"37","author":"McDermott","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.jtcvs.2026.07.002_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2025.15350","article-title":"Efficacy of intravenous immunoglobulin in eliminating de novo donor-specific antibodies after lung transplantation: importance of early intervention","volume":"38","author":"Vorstandlechner","year":"2025","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.jtcvs.2026.07.002_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ajt.2022.12.019","article-title":"Preemptive treatment of de novo donor-specific antibodies in lung transplant patients reduces subsequent risk of chronic lung allograft dysfunction or death","volume":"23","author":"Keller","year":"2023","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.jtcvs.2026.07.002_bib21","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/ajt.14912","article-title":"Preemptive treatment of early donor-specific antibodies with IgA- and IgM-enriched intravenous human immunoglobulins in lung transplantation","volume":"18","author":"Ius","year":"2018","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.jtcvs.2026.07.002_bib22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ppul.24639","article-title":"Six-year experience with treatment of early donor-specific anti-HLA antibodies in pediatric lung transplantation using a human immunoglobulin-based protocol","volume":"55","author":"Ius","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jtcvs.2026.07.002_bib23","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/ajt.13281","article-title":"Impact of CLAD phenotype on survival after lung retransplantation: a multicenter study","volume":"15","author":"Verleden","year":"2015","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.jtcvs.2026.07.002_bib24","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.healun.2017.07.021","article-title":"Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: definition and grading\u2014a 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation","volume":"36","author":"Snell","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.jtcvs.2026.07.002_bib25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.healun.2007.10.017","article-title":"Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection","volume":"26","author":"Stewart","year":"2007","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jtcvs.2026.07.002_bib26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.healun.2016.01.1223","article-title":"Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation","volume":"35","author":"Levine","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.jtcvs.2026.07.002_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.healun.2014.09.019","article-title":"Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation","volume":"34","author":"Ius","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.jtcvs.2026.07.002_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/pathogens10010004","article-title":"Characteristics of immunoglobulin M type antibodies of different origins from the immunologic and clinical viewpoints and their application in controlling antibody-mediated allograft rejection","volume":"10","author":"Matsuda","year":"2020","journal-title":"Pathogens"},{"issue":"suppl 4","key":"10.1016\/j.jtcvs.2026.07.002_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajt.15844","article-title":"Mechanisms of organ transplant injury mediated by B cells and antibodies: implications for antibody-mediated rejection","volume":"20","author":"Chong","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.jtcvs.2026.07.002_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2024.100889","article-title":"Early and late antibody mediated rejection: which game is the complement playing?","volume":"39","author":"Delsante","year":"2025","journal-title":"Transplant Rev (Orlando)"},{"issue":"7","key":"10.1016\/j.jtcvs.2026.07.002_bib31","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/ajt.14752","article-title":"Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report","volume":"18","author":"Tambur","year":"2018","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.jtcvs.2026.07.002_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.athoracsur.2008.03.073","article-title":"Immunological link between primary graft dysfunction and chronic lung allograft rejection","volume":"86","author":"Bharat","year":"2008","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.jtcvs.2026.07.002_bib33","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/ajt.15687","article-title":"Pseudomonas aeruginosa and acute rejection independently increase the risk of donor-specific antibodies after lung transplantation","volume":"20","author":"Kulkarni","year":"2020","journal-title":"Am J Transplant"},{"issue":"784","key":"10.1016\/j.jtcvs.2026.07.002_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp1349","article-title":"Pseudomonas aeruginosa infection induces intragraft lymphocytotoxicity that triggers lung transplant antibody-mediated rejection","volume":"17","author":"Liao","year":"2025","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.jtcvs.2026.07.002_bib35","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.34067\/KID.0000000000000509","article-title":"New therapies for highly sensitized patients on the waiting list","volume":"5","author":"Vo","year":"2024","journal-title":"Kidney360"},{"issue":"3","key":"10.1016\/j.jtcvs.2026.07.002_bib36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"Rachid","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtcvs.2026.07.002_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2025.100386","article-title":"CD38-targeted therapy with daratumumab in clinical lung transplantation: a single-center experience","volume":"10","author":"Hillebrand","year":"2025","journal-title":"JHLT Open"},{"issue":"12","key":"10.1016\/j.jtcvs.2026.07.002_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70415","article-title":"Belatacept-based immunosuppression and donor-specific antibodies in lung transplant: a multi-institutional retrospective study","volume":"39","author":"Younis","year":"2025","journal-title":"Clin Transplant"},{"issue":"9","key":"10.1016\/j.jtcvs.2026.07.002_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/10600280231213112","article-title":"A complement to traditional treatments for antibody-mediated rejection? Use of eculizumab in lung transplantation: a review and early center experience","volume":"58","author":"Kleiboeker","year":"2024","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.jtcvs.2026.07.002_bib40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ajt.2022.11.025","article-title":"First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report","volume":"23","author":"Roux","year":"2023","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.jtcvs.2026.07.002_bib41","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.healun.2024.11.033","article-title":"Basiliximab induction immunosuppression and lung transplant outcomes: propensity analysis in a multicenter cohort","volume":"44","author":"Rim","year":"2025","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.jtcvs.2026.07.002_bib42","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.healun.2025.03.015","article-title":"Molecular criteria for pulmonary antibody-mediated rejection are associated with an increased risk of allograft failure","volume":"44","author":"Keller","year":"2025","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.jtcvs.2026.07.002_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.healun.2025.08.007","article-title":"Diagnostic significance of intragraft donor-specific anti-HLA antibodies in pulmonary antibody-mediated rejection","volume":"45","author":"Hirschi","year":"2026","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.jtcvs.2026.07.002_bib44","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02292-2019","article-title":"Late-onset \"acute fibrinous and organising pneumonia\" impairs long-term lung allograft function and survival","volume":"56","author":"Vanstapel","year":"2020","journal-title":"Eur Respir J"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522326011487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522326011487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:48:59Z","timestamp":1786564139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522326011487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"alternative-id":["S0022522326011487"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2026.07.002","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and treatment of early detectable donor-specific antihuman leukocyte antigen antibodies after lung transplantation: Insights from a 12-year experience","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery.","name":"copyright","label":"Copyright"}]}}